BioMarin Pharmaceutical Inc. - U.S. Food and Drug …
https://investors.biomarin.com/news/news-details/2023/U.S.-Food-and-Drug-Administration-Approves-BioMarins-ROCTAVIAN-valoctocogene-roxaparvovec-rvox-the-First-and-Only-Gene-Therapy-for-Adults-with-Severe-Hemophilia-A-06-29-2023/default.aspx
WEBSAN RAFAEL, Calif., June 29, 2023 / PRNewswire / -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today announced that the United States Food and Drug Administration (FDA) approved ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) gene therapy for …
DA: 99 PA: 87 MOZ Rank: 43